

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 and major arterial and venous thrombotic diseases, long-term neurologic outcomes of COVID-19, “twindemic” of influenza and COVID-19

Peer reviewed journals featured:

- A randomised controlled trial of helmet non-invasive ventilation in acute hypoxemic respiratory failure due to COVID-19 [here](#)
- Observational studies on:
 - COVID-19 and major arterial and venous thrombotic diseases [here](#)
 - Long-term neurologic outcomes of COVID-19 [here](#)
 - Brain neuronal and glial damage during acute COVID-19 infection [here](#)
 - Assessment of the effectiveness of tocilizumab on mortality and progression to mechanical ventilation or intensive care in patients with COVID-19 [here](#)
 - Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes [here](#) and associated editorial [here](#)
 - Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during Delta and Omicron variant predominance period [here](#)
 - Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses [here](#)
- Commentary on
 - The “twindemic” of influenza and COVID-19 [here](#)
 - What the UK can learn from the EU’s COVID plan for winter 2022-23 [here](#)
- An ethics analysis on visitor bans, freedom of association, COVID-19 and the hospital ward [here](#)

Letters and correspondence discussed:

- Characterising adults in Scotland who are not vaccinated against COVID-19 [here](#)
- The needs of UK patients with long COVID [here](#)
- Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 variants after fourth vaccination or tixagevimab and cilgavimab administration in patients with cancer [here](#)
- Hospitalisation for COVID-19 after 3 vs 2 doses of mRNA vaccine by time since booster [here](#)
- SARS-CoV-2 infection and new-onset type 1 diabetes among paediatric patients [here](#)

Pre-peer review articles featured:

- Alterations in smell or taste in individuals infected with SARS-CoV-2 during Omicron wave [here](#)
- SARS-CoV-2 Omicron boosting and B cell response in humans [here](#)
- Omicron subvariants: clinical, laboratory, and cell culture characterisation [here](#)
- Duration of viral infectiousness and correlation with symptoms and diagnostic testing in non-hospitalised adults during acute SARS-CoV-2 infection [here](#)
- Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19 [here](#)
- Biological heterogeneity in patients with post-acute sequelae of COVID-19 [here](#)

Guidance and reports

- The World Health Organization published its weekly epidemiological report [here](#)
- The BMJ released an updated practice pointer for primary care on long COVID [here](#)
- The Australian Technical Advisory Group on Immunisation (ATAGI) published updated guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The Therapeutic Goods Administration (TGA) approved Pfizer's COVID-19 vaccine booster for individuals 5 years and older [here](#)

News and blogs

- Cases rise in England and Wales as hospital admissions remain steady [here](#)
- How long COVID is shedding light on post-viral syndromes [here](#)
- COVID-19: Learning from our differences [here](#)
- SARS-CoV-2 infection protects against dengue [here](#)
- UK parents are urged to vaccinate 2–3-year-olds against flu as NHS warns of “twindemic” [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).